| 1 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
FOXA2 and OTX2 |
|
The purity of the STEM-PD batch was assessed by flow cytometry based on the proportion of cells co-expressing FOXA2 and OTX2. These markers indicated that the cells had been correctly differentiated toward a ventral midbrain progenitor identity. |
This follows the principle of identity-based cellular purity assessment. Product purity is determined by quantifying cells that simultaneously express lineage- and region-specific markers. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI assists clinicians by detecting abnormalities, classifying lesions, segmenting anatomical structures, and prioritizing urgent cases. These functions support faster and more consistent interpretation of medical images. |
This is based on the principle of clinical decision support, in which AI augments rather than replaces human expertise by transforming image data into clinically relevant information that improves diagnostic performance and treatment decisions. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI can independently analyze medical images and highlight suspicious findings for the radiologist to review. This provides an additional layer of assessment that may reduce missed abnormalities and improve diagnostic consistency. |
This is based on the principles of computer-aided diagnosis and clinical decision support, in which AI serves as an adjunctive reviewer rather than replacing the physician. Combining algorithmic analysis with expert judgment can improve sensitivity, error detection, and diagnostic reliability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy refers to the ability to understand how AI systems work, what they can and cannot do, and how their outputs should be interpreted and used appropriately. |
The concept is based on digital and technological literacy, which includes knowledge, critical evaluation, responsible use, and awareness of ethical risks such as bias, privacy, and accountability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
AI acceptability is influenced by clinically relevant and organizational factors, such as trust in the system, understanding of how it works, compatibility with existing workflows, and openness to new technology. The physical color of an AI device is not a meaningful determinant of professional adoption. |
The Technology Acceptance Model and implementation science principles propose that adoption is primarily shaped by perceived usefulness, usability, trust, system understanding, and workflow compatibility. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Healthcare professionals' willingness to use AI depends on opinions, expectations, and practices of colleagues, supervisors, and organizations. Social influence shapes their intention to adopt AI. |
Under the Unified Theory of Acceptance and Use of Technology (UTAUT), social influence refers to the degree to which individuals perceive that important people or institutions expect them to use a technology. It affects behavioral intention rather than directly determining AI’s technical accuracy or financial budget. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
Healthcare professionals may see AI as a threat to their roles, job security, autonomy, or decision-making authority, which can reduce their willingness to adopt AI even when it is meant to support clinicians. |
This reflects the perceived threat and professional displacement anxiety in technology adoption theory. When users believe that a technology may diminish their role, status, or control, they are more likely to resist its implementation. Effective adoption, therefore, requires role clarification, human oversight, and positioning AI as an augmentative clinical tool. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Medical professionals are more likely to accept AI when it is designed around their clinical needs, supports existing workflows, is understandable, and preserves human oversight. High algorithmic performance alone does not guarantee practical adoption. |
Human-centered design and sociotechnical integration emphasize that successful AI relies on aligning technology, users, clinical tasks, organizational context, trust, and accountability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The system-usage category concerns whether AI provides clear clinical value and can be incorporated into existing healthcare workflows without creating unnecessary disruption or workload. |
This reflects the principle of workflow compatibility and perceived usefulness. Technology adoption is more likely when a system delivers measurable benefits, fits routine tasks, and supports efficient clinical decision-making. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Healthcare professionals are more likely to accept AI when its use aligns with principles such as patient safety, fairness, privacy, transparency, and professional responsibility. |
This principle of ethical congruence suggests that the adoption of technology is influenced by whether the system’s functioning and outcomes align with users’ professional standards and moral duties. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
Future studies should examine not only whether healthcare professionals intend to use AI, but also how they interact with it in real clinical settings and how well it fits existing workflows, responsibilities, and organizational structures. |
Human-centered design and sociotechnical systems theory should view technology adoption as an outcome of interactions among users, technical systems, clinical tasks, and organizational contexts. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Human embryonic stem cells are pluripotent and can be differentiated into midbrain dopaminergic neuron progenitors. After transplantation, these cells are intended to survive, mature, release dopamine, and partially restore nigrostriatal neural signaling. |
The main principle is cell replacement therapy: replacing the specific neuronal population lost in Parkinson’s disease to restore dopamine production and improve neural circuit function. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Rats |
|
The STEM-PD cell product was evaluated in rats before human clinical testing. A GLP study assessed toxicity, tumorigenicity, and biodistribution. |
The underlying principle is the validation of preclinical safety and efficacy. The animal model must demonstrate that the transplanted cells do not produce unacceptable toxicity or tumors and that they can survive, differentiate, produce dopamine, and improve Parkinsonian motor deficits. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
9 months |
|
The STEM-PD product underwent a 39-week GLP safety study, approximately 9 months, to evaluate toxicity, tumorigenicity, and biodistribution in rats. |
Long-term preclinical safety assessment is based on the principle that cell-based therapies must be monitored over an extended period to detect delayed adverse effects, uncontrolled cell growth, and migration to unintended tissues. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
STEM-PD was developed for a first-in-human Phase I/IIa clinical trial, primarily evaluating the safety and tolerability of transplanted stem-cell-derived dopamine progenitor cells while also collecting preliminary evidence of biological and clinical effects. |
A Phase I/IIa trial combines initial safety and dose assessment with an early exploratory evaluation of therapeutic activity before larger confirmatory efficacy trials are conducted. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD cell product was manufactured using a standardized GMP-compliant differentiation and cryopreservation process. It was also quality-tested both in vitro and in vivo to satisfy regulatory requirements for consistency, purity, and safety. |
Good Manufacturing Practice (GMP) ensures that advanced cell-therapy products are produced through controlled, documented, reproducible, and quality-assured processes, minimizing contamination and batch-to-batch variability. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
During the 39-week GLP safety study, the transplanted STEM-PD cells caused no observed adverse effects or tumor formation. The study also assessed toxicity, tumorigenicity, and biodistribution as key safety endpoints. |
Preclinical safety of a cell-based therapy is established by demonstrating acceptable toxicity, tumorigenicity, and biodistribution profiles over an extended observation period. The absence of harmful effects and uncontrolled cell growth supports progression to early-phase clinical testing. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The transplanted STEM-PD cells survived, developed into functional dopaminergic neurons, and produced full functional recovery in a preclinical rat model of Parkinson’s disease. |
This demonstrates functional efficacy, meaning that a treatment must produce measurable improvement in disease-related function—not merely cell survival or marker expression. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
FGF8b and SHH provide developmental signals that guide stem-cell-derived neural progenitors toward a ventral midbrain dopaminergic identity, rather than allowing random or spontaneous differentiation. |
This is based on morphogen-directed cell-fate specification. SHH promotes ventral neural identity, while FGF8b contributes to midbrain regional patterning; their controlled timing and concentration help produce the intended dopaminergic progenitor population. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
The rat model was used to determine whether transplanted STEM-PD cells could restore dopamine-related neural function and improve movement deficits associated with Parkinson’s disease. |
Principle of functional efficacy assessment, in which a therapy is evaluated by measurable improvement in disease-relevant behavior or physiological function, rather than by cell survival alone. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|